SciSparc

Historical price data

SciSparc is a clinical-stage biotech focused on developing optimized cannabinoid-based combination therapies for CNS disorders. Its mission is to create safer, more effective pharmaceutical treatments by synergistically combining cannabinoids with approved drugs. Key achievements include advancing its lead candidate for Tourette syndrome into a Phase IIb trial and securing intellectual property for its platform. The strategy is to de-risk development by repurposing known molecules while building a pipeline anchored in proprietary synergistic combinations.

Proprietary platform developing synergistic combination therapies that pair specific cannabinoids (THC, CBD) with other FDA-approved drugs to enhance efficacy and improve safety profiles for CNS disorders.

Faces competition from generic drugs in Tourette's, newly approved agents in Alzheimer's agitation, and other cannabinoid pharma companies. Differentiation hinges on demonstrating superior efficacy/safety from its proprietary synergistic combinations.